6704.TWO Gwo Xi Stem Cell Applied Technology Co. , Ltd

Healthcare Biotechnology Taiwan OTC Exchange
20.00 TWD
Close of Nov 6, 2026
18.00 28.90
Market cap
TWD 2.12B
P/E
-
P/B
2.87x
ROE
-13.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6704.TWO undervalued?

Graham number

The Graham number of Gwo Xi Stem Cell Applied Technology Co. , Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gwo Xi Stem Cell Applied Technology Co. , Ltd fundamental analysis

No fundamental analysis for Gwo Xi Stem Cell Applied Technology Co. , Ltd yet.

Gwo Xi Stem Cell Applied Technology Co. , Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gwo Xi Stem Cell Applied Technology Co. , Ltd

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-der…

Full company profile